Takeda's revenue has held near 1.1 to 1.2 trillion yen across the ten reported quarters, with operating margin recovering from -7.1% in 2024Q4 to 17.3% in 2026Q2, suggesting cost discipline is gaining traction.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been broadly flat at roughly 1.1 to 1.2 trillion yen while operating margin rebounded to 17.3% in 2026Q2 from a loss-making -7.1% in 2024Q4, though gross margin of 48.8% to 68.0% still trails innovative peers.
Positive outcomes from clinical trials could drive a re-rating of the stock towards analyst highs.
Improved guidance following quarterly results may enhance investor confidence and stock performance.
Achieving cost synergies could lead to improved margins and a re-rating of the stock.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.39+24.3% vs $0.31 | $7.5B+2.9% vs $7.3B |
Q3 2026 Jul 30, 2026 | $0.23+33.2% vs $0.17 | $7.7B+7.4% vs $7.1B |
Q2 2026 May 13, 2026 | -$0.05-123.4% vs $0.21 | $6.9B-3.0% vs $7.1B |
Q1 2026 Jan 29, 2026 | $0.21-61.3% vs $0.55 | $7.7B+2.5% vs $7.5B |
VEA dominates international portfolios, but a smaller rival fund uses a completely different logic to pick foreign stocks, and over the past five years it has quietly beaten the giant on both returns and income.
Heritage Investors Management Corp cut its holdings in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 63.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,189 shares of the company's stock after selling 51,750 shares during the period.
Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but operating cash flow declined to $2.74B, highlighting weak underlying cash generation. New products like Mimrylo and Orzeyful are slow to ramp and currently contribute minimally, while Entyvio remains the key revenue driver.
Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability.
Benchmark TAK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Takeda Pharmaceutical Company Limited (TAK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.02 | $66.87B | 27.66 | 4.28% | 8.16% | 5.08% | 2.92% | |
| $40.31 | $179B | 10.58 | 6.43% | 33.94% | 54.09% | 4.3% | |
| $186.43 | $290.83B | 26.47 | 8.63% | 17.68% | 22.18% | 1.71% | |
| $47.04 | $112.95B | 24.24 | 5.49% | 8.19% | 5.81% | 5.23% | |
| $162.55 | $308.96B | 30.86 | 5.97% | 17.82% | 24.32% | 2.47% | |
| $50.33 | $100.84B | 17.69 | 4.11% | 12.96% | 23.31% | 3.23% |
Takeda Pharmaceutical Company Limited (TAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TAK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Takeda Pharmaceutical Company Limited (TAK) stock FAQ — growth, dividends, profitability & financials explained
Takeda Pharmaceutical Company Limited (TAK) reported $4.73T in revenue over the trailing twelve months. Revenue was $4.78T in fiscal year 2025. That is 396% more than the $963.48B of fiscal year 2000.
Takeda Pharmaceutical Company Limited (TAK) grew revenue by 7.2% over the trailing twelve months, compared with the twelve months before.
Yes. Takeda Pharmaceutical Company Limited (TAK) earned $386.37B in net income over the trailing twelve months (a 8.2% net margin).
Yes. Takeda Pharmaceutical Company Limited (TAK) pays a dividend that yields 2.92% at the current price, a moderate yield.
Takeda Pharmaceutical Company Limited (TAK) had a return on equity (ROE) of 5.1% over the trailing twelve months. That is below the market's typical 10-15%.
Takeda Pharmaceutical Company Limited (TAK) generated $447.47B in free cash flow over the trailing twelve months.
